R Squared’s Castle Biosciences CSTL Stock Holding History

R Squared’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,590	Closed	-$42.4K	–	580
2024 Q4	$42.4K	Buy	+1,590	New	+$48.4K	0.04%	562

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

R Squared's CSTL Position: Q1 2025 in Review

R Squared sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 1,590 shares — an estimated $42.4K sold.

R Squared first reported a position in CSTL in Q4 2024 and held it in 1 quarter. The position peaked at $42.4K in Q4 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

R Squared reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,590 Castle Biosciences shares in Q1 2025, an estimated $42.4K.
R Squared first reported a position in Castle Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Castle Biosciences position peaked at $42.4K in Q4 2024.
180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.